Tradestie Institutional Equity Comparison Engine

BCAX vs MGTX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MGTX Overall Edge

MGTX Captures Institutional Edge (4โ€“0 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to MeiraGTx Holdings plc Ordinary Shares (MGTX) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, BCAX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MGTX at 64.1x Forward P/E and 44.8% operating margin (+1074.1% YoY). In options structure, BCAX sits in BREAKDOWN (23rd %ile IV; Dealer Gamma Walls on Pro) against MGTX sits in BREAKDOWN (3rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MGTX
BCAX N/M vs MGTX 64.1x Fwd P/E
Growth & Margin Winner MGTX
Op Margin 0.0% vs 44.8% ยท YoY +0.0% vs +1074.1%
Momentum & Technical Winner MGTX
1Y -31.6% vs +5.8% ยท 52W Pos 8% vs 24%
Options & Structure Winner MGTX
BREAKDOWN (23rd %ile IV) vs BREAKDOWN (3rd %ile IV)
BCAX NASDAQ
Bicara Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$9.75
-2.69% 1D
Market Cap $665.2M
1M Return -41.9%
1Y Return -31.63%
Forward P/E N/M
Unified AI Score
52.1 / 100 HOLD
Tech 58.0 Fund 66.0 Flow 68.0 Mom 64.0
MGTX NASDAQ
MeiraGTx Holdings plc Ordinary Shares
Biological Products, (No Disgnostic Substances)
$8.74
-4.79% 1D
Market Cap $897.2M
1M Return -5.82%
1Y Return +5.81%
Forward P/E 64.1x
Unified AI Score
43.7 / 100 HOLD
Tech 33.0 Fund 58.0 Flow 70.0 Mom 58.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BCAX -31.63% MGTX +5.81% Spread: +37.44 pp (MGTX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BCAX TTM Op. Margin: 0.0% MGTX TTM Op. Margin: 44.8%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BCAX vs MGTX. Trailing 12-month operating profitability (BCAX 0.0% vs MGTX 44.8%) and valuation multiples (BCAX N/M vs MGTX 64.1x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BCAX (1) vs MGTX (9)
Institutional Metric BCAX MGTX Criterion Row Winner
Market Capitalization Scale $665.2M $897.2M Larger Scale MGTX
Trailing P/E Ratio Valuation N/M 10.6x Lower Multiple MGTX
Forward P/E Ratio Valuation N/M 64.1x Lower Multiple MGTX
Revenue Growth (YoY) Growth +0.0% +1074.1% Higher Growth MGTX
Operating Margin (TTM) Profitability 0.0% 44.8% Higher Margin MGTX
Net Profit Margin Profitability 0.0% 19.5% Higher Margin MGTX
Return on Equity (ROE) Capital Efficiency -54.2% 89.5% Higher ROE MGTX
52-Week Range Position Momentum 8% ($8โ€“$31) 24% ($7โ€“$15) Stronger Trend MGTX
Beta / 30D Volatility Risk Regime 1.42ฮฒ ยท 184% Vol 1.66ฮฒ ยท 69% Vol Lower Realized Risk MGTX
Unified Institutional Score Composite Signal 52.1 / 100 (HOLD) 43.7 / 100 (HOLD) Higher Composite BCAX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BCAX vs MGTX Buy Guide
BCAX BREAKDOWN
93d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live BCAX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MGTX BREAKDOWN
62d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 3rd %ile
IV Regime Compressed (<25th %ile)
Live MGTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BCAX nor MGTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.